The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis

Future Oncology

Volumn 6, Issue 9, 2010, Pages 1387-1394

  Ströhlein, Michael A ^a   Heiss, Markus M ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

ascites; bispecific; catumaxomab; EpCAM; intraperitoneal immunotherapy; peritoneal carcinomatosis; trifunctional antibody

Indexed keywords

CATUMAXOMAB; EPITHELIAL CELL ADHESION MOLECULE;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ASCITES TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; DRUG DOSE ESCALATION; DRUG FEVER; DRUG MECHANISM; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; NAUSEA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; ASCITES; CARCINOMA; HUMANS; INFUSIONS, PARENTERAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; PERITONEAL NEOPLASMS;

EID: 77957941980     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.111     Document Type: Review

References (38)

1. Gunderson Ll, Sosin H, Levitt S: Extrapelvic colon - areas of failure in a reoperation series: implications for adjuvant therapy. Int. J. Radiat. Oncol. Biol. Phys. 11(4), 731-741 (1985).
2. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP: Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann. Surg. 243(2), 212-222 (2006).
3. Sugarbaker PH, Cunliffe WJ, Belliveau J et al.: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin. Oncol. 16(4 Suppl. 6), 83-97 (1989).
4. Jayne Dg, Fook S, Loi C, Seow-Choen F: Peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 89(12), 1545-1550 (2002).
5. Parsons SL, Lang MW, Steele RJ: Malignant ascites: a 2-year review from a teaching hospital. Eur. J. Surg. Oncol. 22(3), 237-239 (1996).
6. Sadeghi B, Arvieux C, Glehen O et al.: Peritoneal carcinomatosis from nongynecologic malignancies: results of the evocape 1 multicentric prospective study. Cancer 88(2), 358-363 (2000).
7. Arnold D, Lordick F: Systemic treatment of peritoneal metastases. Chirurg 78(12), 1117-1122 (2007).
8. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63(2), 364-367 (1989).
9. Verwaal VJ, Van Ruth S, De Bree E et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 21(20), 3737-3743 (2003).
10. Elias D, Gilly F, Boutitie F et al.: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric french study. J. Clin. Oncol. 28(1), 63-68 (2010).
11. Glehen O, Gilly FN, Arvieux C et al.: Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann. Surg. Oncol. DOI 10.1245/s10434-010-1039-7 (2010) (Epub ahead of print).
12. Sugarbaker PH, Alderman R, Edwards G et al.: Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann. Surg. Oncol. 13(5), 635-644 (2006).
13. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO: Ep-cam: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell. Biol. 125(2), 437-446 (1994).
14. Amann M, Brischwein K, Lutterbuese P et al.: Therapeutic window of mus110, a single-chain antibody construct bispecific for murine epcam and murine CD3. Cancer Res. 68(1), 143-151 (2008).
15. Went PT, Lugli A, Meier S et al.: Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 35(1), 122-128 (2004).
16. Went P, Vasei M, Bubendorf L et al.: Frequent high-level expression of the immunotherapeutic target Ep-Cam in colon, stomach, prostate and lung cancers. Br. J. Cancer 94(1), 128-135 (2006).
17. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O: The carcinoma-associated antigen EpCam upregulates c-myc and induces cell proliferation. Oncogene 23(34), 5748-5758 (2004).
18. Osta Wa, Chen Y, Mikhitarian K et al.: EpCam is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 64(16), 5818-5824 (2004).
19. Kurtz Je, Dufour P: Adecatumumab: an anti-EpCam monoclonal antibody, from the bench to the bedside. Expert Opin. Biol. Ther. 10(6), 951-958 (2010).
20. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975).
21. Peipp M, Valerius T: Bispecific antibodies targeting cancer cells. Biochem. Soc. Trans. 30(4), 507-511 (2002).
22. Baeuerle PA, Kufer P, Lutterbuse R: Bispecific antibodies for polyclonal T-cell engagement. Curr. Opin. Mol. Ther. 5(4), 413-419 (2003).
23. Haas C, Krinner E, Brischwein K et al.: Mode of cytotoxic action of T cell-engaging bite antibody MT110. Immunobiology 214(6), 441-453 (2009).
24. Kufer P, Lutterbuse R, Baeuerle PA: A revival of bispecific antibodies. Trends Biotechnol. 22(5), 238-244 (2004).
25. Lindhofer H, Mocikat R, Steipe B, Thierfelder S: Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 155(1), 219-225 (1995).
26. Lindhofer H, Menzel H, Gunther W, Hultner L, Thierfelder S: Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. Blood 88(12), 4651-4658 (1996).
27. Ruf P, Lindhofer H: Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98(8), 2526-2534 (2001).
28. Zeidler R, Mayer A, Gires O et al.: TNFa contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res. 21(5), 3499-3503 (2001).
29. Zeidler R, Mysliwietz J, Csanady M et al.: The fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br. J. Cancer 83(2), 261-266 (2000).
30. Zeidler R, Reisbach G, Wollenberg B et al.: Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol. 163(3), 1246-1252 (1999).
31. Strohlein MA, Siegel R, Jager M, Lindhofer H, Jauch KW, Heiss MM: Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J. Exp. Clin. Cancer Res. 28, 18 (2009).
32. Strohlein MA, Heiss MM: Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies. J. Surg. Oncol. 100(4), 329-330 (2009).
33. Strohlein MA, Heiss MM: Immunotherapy of peritoneal carcinomatosis. Cancer Treat. Res. 134, 483-491 (2007).
34. Heiss MM, Strohlein MA, Jager M et al.: Immunotherapy of malignant ascites with trifunctional antibodies. Int. J. Cancer 117(3), 435-443 (2005).
35. Burges A, Wimberger P, Kumper C et al.: Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCam X anti-CD3 antibody: a Phase I/II study. Clin. Cancer Res. 13(13), 3899-3905 (2007).
36. Heiss MM, Murawa P, Koralewski P et al.: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized Phase II/III trial. Int. J. Cancer. DOI 10.1002/ijc.25423 (2010) (Epub ahead of print).
37. Seimetz D, Lindhofer H, Bokemeyer C: Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev. DOI 10.1016/j.ctrv.2010.03.001 (2010) (Epub ahead of print).
38. Lindhofer H, Schoberth A, Pelster D, Hess J, Herold J, Jäger M: Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: results from a pivotal Phase II/ III study. J. Clin. Oncol. 27(S15) (2009) (Abstract 3014).